Glutamate, Brain Connectivity and Duration of Untreated Psychosis (DUP)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02034253 |
|
Recruitment Status :
Completed
First Posted : January 13, 2014
Last Update Posted : January 22, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The early stages of schizophrenia are associated with significant decreases in social and intellectual abilities, with more declines in chronic disease. Studies have identified relationships between duration of untreated psychosis (the duration between the onset of positive symptoms and treatment) and worse long term outcomes. However, the neurobiology of this phenomenon and its implications for response to antipsychotic medications remain poorly understood.
Glutamatergic excess altering brain connectivity might provide an explanation for why those with longer duration of untreated psychosis have worse clinical outcomes. The investigators propose to use neuroimaging to study 67 first episode psychosis subjects before and after sixteen weeks of treatment with risperidone, a common antipsychotic. We will measure (1) glutamate and (2) structural and functional brain connectivity and test the hypotheses that glutamatergic abnormalities are present in first episode patients and that longer duration of untreated psychosis is associated with greater connectivity abnormalities that set the stage for poor response to treatment. 67 demographic-matched controls will also be recruited as a comparison group - healthy controls will not receive antipsychotic medication.
The investigator's previous studies have made progress in the understanding of abnormalities in the glutamate system and brain connectivity in unmedicated patients with schizophrenia and modulation of these by antipsychotic medication. Two indices of glutamatergic dysfunction have been identified. While antipsychotic medications appear to modulate glutamate, the disturbance in the relationship between metabolites is not restored with treatment. In addition, the investigators found that both structural and functional connectivity abnormalities in unmedicated patients with schizophrenia predict patients' response to treatment.
To the investigator's knowledge, no other group has performed a study that uses a combination of complementary neuroimaging techniques that will allow generating a broad characterization of glutamatergic function and brain connectivity in first episode psychosis and change with treatment. The results of the proposed studies could suggest a mechanism by which the duration of untreated psychosis is associated with poor treatment response which might lead to new interventions to target the illness.
| Condition or disease | Intervention/treatment |
|---|---|
| Schizophrenia Psychosis Schizoaffective Disorder | Drug: Risperidone |
| Study Type : | Observational |
| Actual Enrollment : | 134 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Prospective |
| Official Title: | Glutamate, Brain Connectivity and Duration of Untreated Psychosis |
| Actual Study Start Date : | January 2014 |
| Actual Primary Completion Date : | November 2018 |
| Actual Study Completion Date : | November 2018 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
first episode psychosis
Unmedicated first episode psychosis patients that wish to enroll in a 16 week treatment regimen with the drug Risperidone.
|
Drug: Risperidone
Patients with psychosis will be provided a 16 week regimen of the antipsychotic drug Risperidone in accordance with standard care.
Other Name: Risperdal |
|
healthy demographic-matched controls
healthy controls will be matched to patients one to one based on: age, smoking status, parental socio-economic status, and gender. Healthy controls must be free from current or past Axis I mental disorders, 1st degree relative current or past Axis I mental disorders, and any other neurological conditions.
|
- Comparison of indices of glutamate as measured by 1H-MRS in unmedicated first episode psychosis patients before and after antipsychotic treatment and with healthy controls. [ Time Frame: Up to 5 years ]
- Comparison of structural and functional brain connectivity in first episode psychosis patients before and after antipsychotic treatment and healthy controls [ Time Frame: Up to 5 years ]Structural brain connectivity (using diffusion tensor imaging) and functional brain connectivity (using resting state connectivity) will be compared between healthy controls and first episode psychosis patients. Additionally within first episode psychosis patients duration of untreated psychosis (DUP) will be correlated with both structural and functional brain connectivity to determine the impact of DUP on both metrics of brain connectivity.
- Evaluation of the contribution of structural and functional connectivity to eventual antipsychotic treatment response in first episode psychosis patients. [ Time Frame: Up to 5 years ]The investigators will evaluate the relationship between both structural brain connectivity (using diffusion tensor imaging) and functional brain connectivity (using resting state connectivity) before treatment and treatment response after 16 weeks of risperidone therapy in first episode psychosis patients.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 17 Years to 35 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
The investigators expect to enroll a total of 67 male and female patients with first episode psychosis and 67 demographic matched controls.
Among patients who participate in research at the University of Alabama at Birmingham (UAB) the approximate gender, ethnic and race distribution is 75% male and 25% female; 1% Hispanic and 99% Non-Hispanic; 54% White, 44% Black, and 1% Asian/Pacific Islander. The gender distribution is consistent with that observed in clinical populations with schizophrenia.
Persons below the age of 17 and above the age of 35 are excluded to minimize the variance in cognitive functioning or brain connectivity that might be attributable to development rather than diagnosis.
Inclusion Criteria:
- Persons with first episode psychosis
- Healthy controls will be matched to first episode psychosis participants on a one to one basis
Exclusion Criteria:
- inability to understand and sign informed consent assessed by the Evaluation to sign Consent form
- diagnosable central nervous system illnesses
- poorly controlled acute or chronic medical conditions aside from psychosis
- history of head trauma with loss of consciousness for > 2 minutes
- active substance abuse or dependence (exclusive of nicotine dependence)
- suspected substance induced psychotic symptoms
- clinically significant symptoms of depression, hypomania, or mania
- patients concomitantly treated with drugs known to affect glutamate, such as: valproate, topiramate, gabapentin, levetiracetam, lamotrigine, lithium, and acamprosate
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02034253
| United States, Alabama | |
| Sparks Center | |
| Birmingham, Alabama, United States, 35294 | |
| Principal Investigator: | Adrienne C. Lahti, MD | University of Alabama at Birmingham, Department of Psychiatry |
| Responsible Party: | Dr. Adrianne C Lahti, Professor and Division Director of Behavioral Neurobiology, University of Alabama at Birmingham |
| ClinicalTrials.gov Identifier: | NCT02034253 |
| Other Study ID Numbers: |
1R01MH102951 ( U.S. NIH Grant/Contract ) |
| First Posted: | January 13, 2014 Key Record Dates |
| Last Update Posted: | January 22, 2019 |
| Last Verified: | January 2019 |
|
duration of untreated psychosis glutamate functional connectivity |
structural connectivity schizophrenia psychosis |
|
Schizophrenia Psychotic Disorders Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders Risperidone Serotonin Antagonists Serotonin Agents Neurotransmitter Agents |
Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Dopamine Antagonists Dopamine Agents |